Prevention of mucositis in bone marrow transplantation: A double blind randomised controlled trial of sucralfate

L. Castagna, E. Benhamou, E. Pedraza, M. Luboinski, M. Forni, I. Brandes, J. L. Pico, P. Y. Dietrich

Research output: Contribution to journalArticle

Abstract

Mucositis is still a leading side effect of high dose chemotherapy and irradiation delivered in autologous and allogeneic bone marrow transplantation. In this double blind randomised study, we tested the efficacy of sucralfate for the prevention of mucositis induced by such conditioning treatments. Treatment was started one day before conditioning regimen and patients were prospectively evaluated. The main endpoint was severe mucositis that was more frequent in the placebo group than in the sucralfate group (47% vs. 29%, P = 0.07). This trend was confirmed after adjustment on total body irradiation (TBI) (P = 0.06), the sole stratification parameter. Interestingly, patients receiving sucralfate showed a significant reduction of diarrhoea (25% vs. 53%, P = 0.005). Overall, the preventive administration of sucralfate appears to be an effective procedure to diminish the occurrence of severe oral and intestinal mucositis in patients treated by high dose chemotherapy alone or combined with TBI before bone marrow transplantation.

Original languageEnglish
Pages (from-to)953-955
Number of pages3
JournalAnnals of Oncology
Volume12
Issue number7
DOIs
Publication statusPublished - 2001

Fingerprint

Sucralfate
Mucositis
Bone Marrow Transplantation
Randomized Controlled Trials
Whole-Body Irradiation
Drug Therapy
Stomatitis
Homologous Transplantation
Double-Blind Method
Diarrhea
Placebos
Therapeutics

Keywords

  • Mucositis
  • Stem-cell transplantation
  • Sucralfate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prevention of mucositis in bone marrow transplantation : A double blind randomised controlled trial of sucralfate. / Castagna, L.; Benhamou, E.; Pedraza, E.; Luboinski, M.; Forni, M.; Brandes, I.; Pico, J. L.; Dietrich, P. Y.

In: Annals of Oncology, Vol. 12, No. 7, 2001, p. 953-955.

Research output: Contribution to journalArticle

Castagna, L, Benhamou, E, Pedraza, E, Luboinski, M, Forni, M, Brandes, I, Pico, JL & Dietrich, PY 2001, 'Prevention of mucositis in bone marrow transplantation: A double blind randomised controlled trial of sucralfate', Annals of Oncology, vol. 12, no. 7, pp. 953-955. https://doi.org/10.1023/A:1011119721267
Castagna, L. ; Benhamou, E. ; Pedraza, E. ; Luboinski, M. ; Forni, M. ; Brandes, I. ; Pico, J. L. ; Dietrich, P. Y. / Prevention of mucositis in bone marrow transplantation : A double blind randomised controlled trial of sucralfate. In: Annals of Oncology. 2001 ; Vol. 12, No. 7. pp. 953-955.
@article{2ad9779db35d4887bb6b83afeba71433,
title = "Prevention of mucositis in bone marrow transplantation: A double blind randomised controlled trial of sucralfate",
abstract = "Mucositis is still a leading side effect of high dose chemotherapy and irradiation delivered in autologous and allogeneic bone marrow transplantation. In this double blind randomised study, we tested the efficacy of sucralfate for the prevention of mucositis induced by such conditioning treatments. Treatment was started one day before conditioning regimen and patients were prospectively evaluated. The main endpoint was severe mucositis that was more frequent in the placebo group than in the sucralfate group (47{\%} vs. 29{\%}, P = 0.07). This trend was confirmed after adjustment on total body irradiation (TBI) (P = 0.06), the sole stratification parameter. Interestingly, patients receiving sucralfate showed a significant reduction of diarrhoea (25{\%} vs. 53{\%}, P = 0.005). Overall, the preventive administration of sucralfate appears to be an effective procedure to diminish the occurrence of severe oral and intestinal mucositis in patients treated by high dose chemotherapy alone or combined with TBI before bone marrow transplantation.",
keywords = "Mucositis, Stem-cell transplantation, Sucralfate",
author = "L. Castagna and E. Benhamou and E. Pedraza and M. Luboinski and M. Forni and I. Brandes and Pico, {J. L.} and Dietrich, {P. Y.}",
year = "2001",
doi = "10.1023/A:1011119721267",
language = "English",
volume = "12",
pages = "953--955",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - Prevention of mucositis in bone marrow transplantation

T2 - A double blind randomised controlled trial of sucralfate

AU - Castagna, L.

AU - Benhamou, E.

AU - Pedraza, E.

AU - Luboinski, M.

AU - Forni, M.

AU - Brandes, I.

AU - Pico, J. L.

AU - Dietrich, P. Y.

PY - 2001

Y1 - 2001

N2 - Mucositis is still a leading side effect of high dose chemotherapy and irradiation delivered in autologous and allogeneic bone marrow transplantation. In this double blind randomised study, we tested the efficacy of sucralfate for the prevention of mucositis induced by such conditioning treatments. Treatment was started one day before conditioning regimen and patients were prospectively evaluated. The main endpoint was severe mucositis that was more frequent in the placebo group than in the sucralfate group (47% vs. 29%, P = 0.07). This trend was confirmed after adjustment on total body irradiation (TBI) (P = 0.06), the sole stratification parameter. Interestingly, patients receiving sucralfate showed a significant reduction of diarrhoea (25% vs. 53%, P = 0.005). Overall, the preventive administration of sucralfate appears to be an effective procedure to diminish the occurrence of severe oral and intestinal mucositis in patients treated by high dose chemotherapy alone or combined with TBI before bone marrow transplantation.

AB - Mucositis is still a leading side effect of high dose chemotherapy and irradiation delivered in autologous and allogeneic bone marrow transplantation. In this double blind randomised study, we tested the efficacy of sucralfate for the prevention of mucositis induced by such conditioning treatments. Treatment was started one day before conditioning regimen and patients were prospectively evaluated. The main endpoint was severe mucositis that was more frequent in the placebo group than in the sucralfate group (47% vs. 29%, P = 0.07). This trend was confirmed after adjustment on total body irradiation (TBI) (P = 0.06), the sole stratification parameter. Interestingly, patients receiving sucralfate showed a significant reduction of diarrhoea (25% vs. 53%, P = 0.005). Overall, the preventive administration of sucralfate appears to be an effective procedure to diminish the occurrence of severe oral and intestinal mucositis in patients treated by high dose chemotherapy alone or combined with TBI before bone marrow transplantation.

KW - Mucositis

KW - Stem-cell transplantation

KW - Sucralfate

UR - http://www.scopus.com/inward/record.url?scp=0034909823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034909823&partnerID=8YFLogxK

U2 - 10.1023/A:1011119721267

DO - 10.1023/A:1011119721267

M3 - Article

C2 - 11521801

AN - SCOPUS:0034909823

VL - 12

SP - 953

EP - 955

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -